Ser103

Site Information
PPAkAEAsPEPGPGP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 27452116

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 )
Disease tissue studied:	breast cancer ( 3 ) , ovarian cancer ( 2 ) , melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , K562 (erythroid) ( 5 ) , OVCAR5 (ovarian) ( 2 ) , WM239A (melanocyte) ( 1 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Ding LW, et al. (2015) LNK (SH2B3): paradoxical effects in ovarian cancer. Oncogene 34, 1463-74 24704825 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
5	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info